Clinical Trials Logo
  1. Home
  2. ANCA-associated Vasculitis
  3. NCT05383573

Pediatric ANCA Associated-vasculitis — PediANCA  

ANCA-Associated Vasculitis Clinical Trial

Official title:
Pediatric ANCA Associated-vasculitis : Latest Clinical Review and Therapeutic Outcomes. A Retrospective Epidemiological Study on a French Cohort

Clinical Trial Summary

The incidence in pediatrics is very low (about 0.5 per million according to a French study) and therefore the data on the pathology very poor, especially on the therapeutic level. Without appropriate treatment, the mortality rate of the pathology is very high. Existing treatments are almost exclusively composed of immunomodulatory and/or immunosuppressive treatments. Complications related to pathology and iatrogeny are among the first causes of mortality from this pathology and deserve to be studied in order to be known and if possible avoided. The purpose of the study is to achieve a national comparison of clinical and therapeutic practices.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05383573
Study type Observational
Source University Hospital, Strasbourg, France
Contact Ariane ZALOSZYC, MD
Phone 33 3 88 12 77 49
Email ariane.zaloszyc@chru-strasbourg.fr
Status Recruiting
Phase
Start date January 1, 2022
Completion date December 31, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02257866 - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Completed NCT02463539 - Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis N/A
Recruiting NCT05897684 - Avacostar - (PASS)
Recruiting NCT05364892 - Biocollection of Patients With ANCA Associated Vasculitis N/A
Terminated NCT00482066 - Abatacept in ANCA Associated Vasculitis Phase 2
Not yet recruiting NCT02126098 - Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis N/A
Recruiting NCT05965284 - Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) Phase 4
Recruiting NCT06285279 - FKC288 in Participants With Autoimmune Kidney Diseases Phase 1
Completed NCT02994927 - A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Phase 3
Recruiting NCT02463578 - Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis N/A
Active, not recruiting NCT05716334 - Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
Completed NCT02222155 - Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis Phase 2
Recruiting NCT05197842 - Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis Phase 1/Phase 2
Completed NCT02954705 - MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS
Completed NCT04280601 - PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis N/A
Active, not recruiting NCT02108860 - Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Phase 3